Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Receivables (2021 - 2025)

Autolus Therapeutics' Receivables history spans 5 years, with the latest figure at $24.9 million for Q4 2025.

  • For Q4 2025, Receivables rose 4823.91% year-over-year to $24.9 million; the TTM value through Dec 2025 reached $24.9 million, up 4823.91%, while the annual FY2025 figure was $24.9 million, 1635.03% up from the prior year.
  • Receivables reached $24.9 million in Q4 2025 per AUTL's latest filing, down from $33.5 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $33.5 million in Q3 2025 to a low of $384000.0 in Q4 2021.
  • Average Receivables over 5 years is $9.0 million, with a median of $1.3 million recorded in 2022.
  • Peak YoY movement for Receivables: plummeted 76.29% in 2024, then soared 5508.7% in 2025.
  • A 5-year view of Receivables shows it stood at $384000.0 in 2021, then soared by 305.21% to $1.6 million in 2022, then crashed by 59.83% to $625000.0 in 2023, then dropped by 19.04% to $506000.0 in 2024, then soared by 4823.91% to $24.9 million in 2025.
  • Per Business Quant, the three most recent readings for AUTL's Receivables are $24.9 million (Q4 2025), $33.5 million (Q3 2025), and $27.3 million (Q2 2025).